RT Journal Article
T1 BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
A1 Dang, Chau
A1 Ewer, Michael S
A1 Delaloge, Suzette
A1 Ferrero, Jean-Marc
A1 Colomer, Ramon
A1 de la Cruz-Merino, Luis
A1 Werner, Theresa L
A1 Dadswell, Katherine
A1 Verrill, Mark
A1 Eiger, Daniel
A1 Sarkar, Sriparna
A1 de Haas, Sanne Lysbet
A1 Restuccia, Eleonora
A1 Swain, Sandra M
K1 cardiac safety
K1 early breast cancer
K1 neoadjuvant
K1 pertuzumab
K1 trastuzumab
AB BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w × 4 ➝ paclitaxel qw × 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w × 4 ➝ docetaxel q3w × 4 (B) as per physician’s choice. Pertuzumab−trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of ≥10% points from baseline to
SN 2072-6694
YR 2022
FD 2022-05-24
LK http://hdl.handle.net/10668/20896
UL http://hdl.handle.net/10668/20896
LA en
DS RISalud
RD Apr 6, 2025